Category: Archive
February 16, 2011
By Staff Reporter
Galen CEO John King said the firm expected to unveil their estradiolacetate intravaginal ring product in the United States in the first half of next year.
Concern about HRTs, which are taken by women to relieve symptoms of the menopause, has risen sharply in recent months after a series of studies showed they increase the risk of breast cancer and strokes.
Galen’s shares, which have underperformed the British pharmaceutical sector by 24 per cent since the start of the year, were 6.2 percent higher in London on the news, valuing the business at about